Citadel Advisors - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 63 filers reported holding PROQR THRAPEUTICS N V in Q1 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.0%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q2 2023$297,419
-35.9%
183,592
-15.7%
0.00%
Q1 2023$463,869
+23.5%
217,779
+114.6%
0.00%
Q4 2022$375,550
+2247.2%
101,500
+381.0%
0.00%
Q3 2022$16,000
-92.0%
21,100
-91.8%
0.00%
Q2 2022$199,000
+610.7%
256,415
+727.1%
0.00%
Q1 2022$28,000
-98.7%
31,000
-88.6%
0.00%
Q4 2021$2,175,000
+23.6%
271,369
+29.2%
0.00%
Q3 2021$1,759,000
+121.8%
210,106
+78.6%
0.00%
Q2 2021$793,000
-10.0%
117,630
-11.7%
0.00%
Q1 2021$881,000
+1195.6%
133,176
+722.1%
0.00%
Q4 2020$68,000
-48.1%
16,200
-25.0%
0.00%
Q2 2020$131,000
-31.1%
21,600
-37.4%
0.00%
Q1 2020$190,000
-50.0%
34,500
-47.7%
0.00%
Q3 2019$380,000
-2.8%
65,996
+53.4%
0.00%
Q2 2019$391,000
-65.8%
43,025
-47.7%
0.00%
-100.0%
Q1 2019$1,142,000
+39.4%
82,339
+58.4%
0.00%
Q4 2018$819,000
+695.1%
51,972
+334.5%
0.00%
Q4 2015$103,000
-48.0%
11,960
-12.3%
0.00%
Q3 2015$198,000
-8.8%
13,636
+4.9%
0.00%
Q2 2015$217,000
+3.3%
13,002
+35.5%
0.00%
Q1 2015$210,000
-88.8%
9,597
-91.2%
0.00%
-100.0%
Q3 2014$1,869,000108,7150.00%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q1 2022
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,237,400$5,197,0001.55%
Prosight Management, LP 255,000$1,071,0000.50%
RTW INVESTMENTS, LP 5,009,768$21,041,0000.35%
Kerrisdale Advisers, LLC 453,182$1,903,0000.15%
Artal Group S.A. 1,196,218$5,024,0000.11%
COWEN AND COMPANY, LLC 285,696$1,200,0000.11%
Golden Green, Inc. 16,999$71,0000.07%
APOGEM CAPITAL LLC 15,855$67,0000.04%
ADAGE CAPITAL PARTNERS GP, L.L.C. 4,550,062$19,110,0000.04%
ALTRINSIC GLOBAL ADVISORS LLC 241,360$1,014,0000.03%
View complete list of PROQR THRAPEUTICS N V shareholders